|Home||About us||Molecular assays||Partnerships & licensing||Investor room||News|
QIAGEN Marseille develops molecular diagnostic tests designed to map diseases in order to guide patients and oncologists’ decisions along their complex therapeutic path.
With more than 60 tests used routinely worldwide for diagnosis, prognosis and follow-up of thousands of patients with blood cancer, QIAGEN Marseille is also developping diagnostic tools targeting other cancers. Its goal is to provide information, remaining unavailable until now, to sustain the development of personalized medicine.
Founded as IPSOGEN in 1999, the company is, since July 2011, a subsidiary of the QIAGEN group, the leading global provider of sample and assay technologies. From January 1st 2013, IPSOGEN has changed its Company name to QIAGEN Marseille. The company, located in Marseille, France, employed 75 people as of December 31, 2013.
Within the QIAGEN Group, Marseille serves as a Center of Excellence: